J. Michael Kilby, MD
Professor of Medicine and
     Microbiology/Immunology
Director, Division of Infectious Diseases
Medical University of South Carolina
Charleston, SC

Research Topics

• Pathogenesis-based clinical trials
• Novel agents for HIV infection
• Immune-based therapies for HIV infection

Lecture and Writing Topics

• Novel treatment strategies for HIV infection
• Clinical management of HIV infection

Current Professional Summary

Dr Kilby is Professor of Medicine and Microbiology/Immunology and Director of the Division of Infectious Diseases at the Medical University of South Carolina (MUSC). He has coordinated AIDS Clinical Trial Group (ACTG), pharmaceutical, and exploratory pathogenesis-based clinical trials. Dr Kilby is also heavily involved in medical student and resident education.

Committees and Organizations

• Medical Research Council of South Africa Grant Study Section, Research Managment Division, Capetown, South Africa (2009)
• HIV Pathogenesis Grant Study Section, Department of Veterans Affairs, Washington, DC (2006)
• Co-char, Acute Infection and Early Disease Research Program (AIEDRP) Treatment Working Group (2000-2004)
• Faculty Mentor, UAB Medical Student Research Society (2000)
• Principal Investigator, NIH-sponsored UAB Acute Infection and Early Disease Research Program (AIEDRP) grant (2000)
• Member and Protocol Chair, AIDS Clinical Trials Group (1998-2000)
• Member, ACTG Therapeutic Immunology Subcommittee (1998-2000)

Honors and Awards

• Nomination by MUSC medical students for "Faculty Excellence Award" (2010)
• Nomination for MUSC Department of Medicine "Excellence in Teaching" Award (2009)
• Community Health Scholars Award (2007)
• Outstand Peer Review Award, Clinical Infectious Diseases (2005)
• Fellow, American College of Physicians (2002)
• Fellow, Infectious Disease Society of America (2002)

Education

• Wake Forest University, BA in English with Honors/Summa Cum Laude (1986)
• University of North Carolina, MD with Honors (1990)
• Duke University, Internal Medicine Residency, Assistant Chief Resident (1993)
• University of Alabama at Birmingham, Infectious Disease Fellowship (1993-1996)

Selected Publications

1. Kilby JM, Lee HY, Hazelwood JD, et al. Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. AIDS. 2008;22:957-962.
2. Kilby JM, Bucy RP, Mildvan D, et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis. 2006;194:1672-1676.
3. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med. 2003;348:2228-2238.
4. Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS. 2003;17:691-698.
5. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307-312.
6. Kilby JM, Goepfert PA, Miller AP, et al. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. Ann Intern Med. 2000;133:435-438.
7. Kilby JM, Sfakianos G, Gizzi N, et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother. 2000;44:2672-2678.
8. Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires K, Sillers M, Mitsuyasu RT, Kilby JM. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest. 1999;103:1391-1398.
9. Hockett RD, Kilby JM, Derdeyn CA, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med. 1999;189:1545-1554.
10. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998;4:1302-1307.

Return to Top